Martin Plöderl Profile picture
Feb 15, 2023 27 tweets 6 min read Read on X
1/ Lithium & suicide: there is some (fierce) discussion about the suicide preventive potential of lithium. Some say it is a fact that lithium prevents suicides. However, an unbiased look at the evidence reveals that there IS uncertainty which should be acknowledged. A thread.
2/ There are meta-analyses concluding that lithium significantly reduced suicides - this one is perhaps the one most often cited

No other psychopharmacological tx has such effects. This is what I also told again and again in my talks, too.bmj.com/content/346/bm…
3/ Moreover, there is no big money in lithium, as it is a cheap medication. Thus it is often assumed that there is less bias in the research.
4/ In our recent MA, however, we concluded that the evidence from randomized controlled trials remains inconclusive, especially from the more recent trials, and that more data is needed. Confidence intervals for suicides are wide.
cambridge.org/core/journals/…
5/ Other meta-analyses came to similar conclusions. Statistical significance depends on the inclusion/exclusion of more recent data or different inclusion criteria (already a hint that the the effect is not robust).


cambridge.org/core/journals/…
cambridge.org/core/journals/…
6/ Moreover, a recent very good RCT was stopped early because it turned out that lithium had no protective effect with respect to suicide attempts.
jamanetwork.com/journals/jamap…
7/ Proponents argue that results of observational studies need to be considered. Fair point, but we know that observ stud can suffer from confounders. @joannamoncrieff argued that patients who stay on lithium have better compliance and thus better prognosis, indep of tx w lithium
8/ Interesting discussion about confounders also here recently on twitter here:
9/ Some proponents point out findings of ecologicial studies: fewer suicides in regions with higher levels of lithium in drinking water. However, after correction of the likely publication bias, the association almost nullifies.
10/ IMO, an under-acknowledged point in the discussion is that the findings for suicides point at a suicide protective effect (wih substantial uncertainty), the there was no such effect for suicide attempts, where statistical power is higher.
11/ This discrepancy is strange and a reason for concern, as fatal and nonfatal suicidal behavior are substantially correlated, and for this reason suicide attempts are often used as a proxy for suicides in many trials in suicidology.
12/ Another challenge is how to aggregate RCTs in meta-analysis when there were no suicides at all (small wonder, given the rarity of suicides). There is no consensus if such evidence should be included. Some specific stats methods are only available recently.
13/ We were accused of including these double-zero trials (leading to larger confidence intervals). It seems critiques are not aware that 1) there's no consensus to include/exclude such trials, and 2) recent statistical papers showing that excluding these trials leads to biases
13/ “To utilize all available information and reduce research waste and avoid overestimating the effect,
meta-analysts should incorporate DZS, rather than simply removing them”
link.springer.com/article/10.100…
14/ “To utilize all available information and reduce research waste and avoid overestimating the effect,
meta-analysts should incorporate DZS, rather than simply removing them”
link.springer.com/article/10.100…
15/ Thus, it is is not only unfair to accuse us of selectively stats methods bc there is no consensus about method is best. Moreover, we applied conventional stats methods in sensitivity analyses w similar conclusions. Seems that some critics are not aware about their own biases.
16/ Furthermore, we don’t know how strong the publication bias is in the trial data. As a rule of thumb, the efficacy of treatments is usually overestimated and the harms underestimated. The extend of this bias remains has still not been adequately addressed for lithium, AFAIK.
17/ Even proponents of lithium admit that there is uncertainty, as we point out in our reply to critics:
“Baldessarini and Tondo [] also recently acknowledged the uncertainty of lithium's anti-suicidal properties, describing how:cambridge.org/core/journals/…
18/ ‘recruiting participants to such trials [suicide prevention trials of lithium] may be made difficult by an evidently prevalent belief that the question of antisuicidal effects of lithium is already settled, which it certainly is not’ "
19/ The uncertainty was also acknowledged in the excellent and IMO balanced discussion of the issue and the need for “An individualized risk/benefit analysis” by Hal Wortzel very recently
journals.lww.com/practicalpsych…
20/ “Conclusions that lithium unequivocally offers suicide prevention benefits do not appear warranted based on the strength of existing studies“
The paper gives good practical advice for prescribers.
21/ Thus, I think there is no way around to acknowledge the uncertainty in the evidence regarding the suicide preventive effect of lithium. Strong conclusions in either direction are not justified. More data is needed.
22/ Sorry for the typos and missing words - I was in a hurry.
23/ More thoughts: what's the necessary size of an RCT to prove that lithium prevents suicides. Some "optimistic" assumptions: lithium prevents 50% of suicides among a high-risk population (eg those after suic attempts, with ca 3% dying by suc in 1st year after the suic attempt)
24/ Such a trial needs ca 2500 patients. But compare this to the actual size of the existing trials.
Image
Image
25/ Using the actual rate of suicides in placebo arms of lithium (ca. 0.5%) as a basis for such a power analysis, you need nearly 15,000 people in a trial.
In ALL trials that were included in our meta-analysis, there were less than 4000 participants. We definitely need more data
@threadreaderapp unroll please

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Martin Plöderl

Martin Plöderl Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PloederlM

Sep 1, 2024
1. Our paper on lithium in drinking water and suicides in Switzerland was just accepted for publication. It is to our knowledge the first pre-registered study on this topic. We found a near perfect null-result. Image
2. Background: lithium is considered to be suicide protective in therapeutic doses and some are convinced it is THE drug in suicide prevention. However, with new evidence, appropriate statistical methods, and results for suic attempts, uncertainty remains
3. There are now ca 20 studies on lithium in drinking water and suicide rates. Overall, results support the suicide preventive powers of lithium bc higher lithium levels were associated with lower suicide rates. Some even suggested to add lithium to tap water.
Read 16 tweets
Jun 6, 2024
1. Beitrag zu Antidepressiva (AD) im geschätzten Kulturradio Ö1 mit einer sympathischen Moderatorin die selber Erfahrungen mit Depressionen und AD hat.
Neben vielen guten Infos sind aber leider einige falsche oder veraltete Infos dabei. Ein 🧵 später
oe1.orf.at/programm/20240…
2. "Psychologische" Absetzsymptome nach langer Einnahme. Falsch. Es gibt gute Hinweise dass problematische Entzugssymptome körperlicher Natur sind. Ja, man darf oder sogar soll dazu Entzugssymptome sagen.
3. Nicht erwähnt wurde: erst seit kurzem werden Absetzprobleme richtig beforscht und evidenzbasierte Ausschleichstrategien entwickelt. Lange wurde das verharmlost, auch in der Psychiatrie. Erst durch Engagement von Betroffenen (darunter Psychiater) änderte sich was.
Read 12 tweets
May 27, 2024
1. Last year @NaudetFlorian and I pointed out severe problems in a review about lithium in drinking water and suicide. The problems are summarized in the thread below. So what happened afterwards?
2. To recap the most severe error: the author correlated suicide-rates w lithium-levels in international studies (each dot is a study). But this was a mix of suic-RATES (per 100,000) and suic-rate-RATIOS standardized to 1 in some studies or to 100 in others. You can't mix this! Image
3. Thus, the main result is completely meaningless. There are many more errors (e.g., using more than one study from the same region).
We wrote a letter and only yesterday I had access to what the editor said in an editorial where he commented on our letter. Take a breath:
Read 7 tweets
Apr 9, 2024
A. A long thread in response to @royperlis, Harvard professor of psychiatry, who recently suggested that SSRIs should be available over the counter, as they “have repeatedly been shown to be safe and effective for treating major depression and anxiety disorders” 1
B. In the following, I will examine some of his arguments, as they are either in contradiction to the evidence or give a biased, uncritical summary on the evidence. I was blocked after saying that the harm/benefit ratio is problematic for the majority. Refs are available online.
C. Are SSRI’s save and effective? The scientific discussion ongoing 2–4. Theaverage efficacy (around 2 points on the Hamilton Depression Scale) in short-term clinical trials is below typical thresholds of clinical significance 5.
Read 36 tweets
Jan 20, 2024
1/ Last year a study was published about escitalopram for GAD for children/adolescents, where it was concluded that ‘Escitalopram reduced anxiety symptoms and was well tolerated.’’. In our letter, we disagreed.
2/ mainly because only the primary outcome was just below the significance threshold, the effect size was likely not clinically meaningful, and there was a significantly higher risk for suicide ideation (not discussed at all in the paper) and adverse events with esc than placebo
3/ All 6 secondary outcomes were not significant and close to zero. Thus, the findings are just not compatible with the author’s conclusion.
Now the authors responded (paywalled)
liebertpub.com/doi/full/10.10…
Read 21 tweets
Jul 10, 2023
1/ Escitalopram now approved for generalized anxiety disorders for children & adolescents. FDA considers it as safe and effective for this new indication, based on a recent RCT. Let's have a look at this trial ->
2/ In the RCT, Strawn et al. (2023) concluded that “Escitalopram reduced anxiety symptoms and was well tolerated”. But this conclusion is not supported by the data presented.
liebertpub.com/doi/full/10.10…
3/ Efficacy, according to the primary outcome, is small, with a standardized mean difference of 0.27 (not reported in paper).
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(